Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction
Audrey H. Wu,Keith D. Aaronson,Steven F. Bolling,Francis D. Pagani,Kathy Welch,Todd M. Koelling +5 more
Reads0
Chats0
TLDR
There is no clearly demonstrable mortality benefit conferred by MVA for significant MR with severe LV dysfunction, and a prospective randomized control trial is warranted for further study of mortality with MVA in this population.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2005-02-01 and is currently open access. It has received 637 citations till now. The article focuses on the topics: Mitral valve annuloplasty & Mitral regurgitation.read more
Citations
More filters
Journal ArticleDOI
Reply: Is papillary muscle approximation the answer to absent reverse remodeling in transcatheter edge-to-edge repair and reductive mitral annuloplasty?
Journal ArticleDOI
Impact of Ischemic Mitral Regurgitation on Long-Term Outcome of Patients With Ejection Fraction Above 0.30 Undergoing First Isolated Myocardial Revascularization
Journal ArticleDOI
Outcomes and predictors of patients with moderate or severe functional mitral regurgitation and nonischemic dilated cardiomyopathy.
Jiangtao Li,Xiang Wei +1 more
TL;DR: In this article , the authors compared the clinical outcomes between different treatment strategies and identify predictors associated with the adverse outcomes in patients with functional mitral regurgitation (FMR) and nonischemic dilated cardiomyopathy (DCM).
Journal ArticleDOI
The Prognostic Impact of Exercise-Induced Worsening of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Myocardial Ischemia
TL;DR: “Ischemic mitral regurgitation” is convenient shorthand for functional MR caused by changes in ventricular structure and function, ultimately‐but not necessarily directly ‐ related to the effects of ischemia.
References
More filters
Journal ArticleDOI
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Arthur J. Moss,Wojciech Zareba,W. Jackson Hall,Helmut U. Klein,David J. Wilber,David S. Cannom,James P. Daubert,Steven L. Higgins,Mary W. Brown,Mark L. Andrews +9 more
TL;DR: In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy.
Journal ArticleDOI
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Michael R. Bristow,Leslie A. Saxon,John P. Boehmer,Steven K. Krueger,David A. Kass,Teresa De Marco,Peter E. Carson,Lorenzo DiCarlo,David L. DeMets,Bill G. White,Dale W DeVries,Arthur M. Feldman +11 more
TL;DR: In this paper, the authors tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays.
Journal ArticleDOI
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more